CD117 (Kit) or C-Kit is a growth factor receptor on mast cells. When a molecule called stem cell factor attaches to C-Kit, the development of mast cells results. A mutation of the receptor causes ...

Fintel reports that on September 9, 2024, JMP Securities initiated coverage of Jasper Therapeutics (NasdaqCM:JSPR) with a ...

Immunohistochemical profiles typically include positivity for CD117 and CK7. ESC-RCCs generally have a benign clinical course, but a small subset may exhibit aggressive behavior, necessitating careful ...

REDWOOD CITY, Calif., Sept. 10, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company ...

A Spanish study that investigated the prognostic value of immunophenotyping in patients with multiple myeloma has found that expression of the antigens CD19, CD28 and CD117 are significantly ...

9月13日，中国货币网公告显示，承德银行股份有限公司发行2024年第117期同业存单，简称：24承德银行CD117，发行收益率2.11%，期限1年，实际发行量2.5亿元。

9月12日，中国货币网公告显示，柳州银行股份有限公司发行2024年第117期同业存单，简称：24柳州银行CD117，发行收益率2.12%，期限6个月，实际发行量0.8亿元。

REDWOOD CITY, Calif. - 生物技术公司Jasper Therapeutics, Inc. (NASDAQ:JSPR)今天宣布，已获得加拿大卫生部批准，可以开始进行briquilimab治疗哮喘的1b/2a期临床试验。这一监管里程碑允许公司开始招募患者参与研究，计划于2024年第四季度开始给药。 该临床试验旨在评估单剂180mg briquilimab对哮喘患者的疗效。这项双盲、 ...

Briquilimab (formerly JSP191) is a targeted aglycosylated monoclonal antibody that blocks stem cell factor from binding to the cell-surface receptor c-Kit, also known as CD117, thereby inhibiting ...